The Herpes Zoster (Shingles) drugs in development market research report provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Herpes Zoster (Shingles). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued products.

GlobalData tracks 44 drugs in development for Herpes Zoster (Shingles) by 44 companies/universities/institutes. The top development phase for Herpes Zoster (Shingles) is preclinical with 17 drugs in that stage. The Herpes Zoster (Shingles) pipeline has 43 drugs in development by companies and one by universities/ institutes. Some of the companies in the Herpes Zoster (Shingles) pipeline products market are: BioNTech, Pfizer and Shulov Innovative Science.

The key targets in the Herpes Zoster (Shingles) pipeline products market include Interferon Alpha/Beta Receptor 1 (Cytokine Receptor Class II Member 1 or Cytokine Receptor Family 2 Member 1 or Type I Interferon Receptor 1 or IFNAR1), Interferon Alpha/Beta Receptor 2 (Interferon Alpha Binding Protein or Type I Interferon Receptor 2 or IFNAR2), and Varicella zoster virus Envelope glycoprotein E (gE).

The key mechanisms of action in the Herpes Zoster (Shingles) pipeline product include Interferon Alpha/Beta Receptor 1 (Cytokine Receptor Class II Member 1 or Cytokine Receptor Family 2 Member 1 or Type I Interferon Receptor 1 or IFNAR1) Agonist with five drugs in Phase III. The Herpes Zoster (Shingles) pipeline products include five routes of administration with the top ROA being Intramuscular and ten key molecule types in the Herpes Zoster (Shingles) pipeline products market including Subunit Vaccine, and mRNA Vaccine.

Herpes Zoster (Shingles) overview

Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain, and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.

For a complete picture of Herpes Zoster (Shingles)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.